<DOC>
	<DOCNO>NCT00394992</DOCNO>
	<brief_summary>The primary aim study investigate whether addition new anti-cancer drug bevacizumab ( Avastin ) combination chemotherapeutic agent capecitabine ( Xeloda ) oxaliplatin ( Eloxatin ) reduce ( slows ) recurrence metastatic disease radical resection liver metastases patient colorectal cancer .</brief_summary>
	<brief_title>Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection Liver Metastasis Colorectal Cancer</brief_title>
	<detailed_description>The primary therapy colorectal cancer surgical resection , half colorectal cancer patient eventually die metastatic disease . Although introduction new anticancer agent efficacy metastatic colorectal cancer , e.g . : oxaliplatin irinotecan , targeted agent cetuximab bevacizumab change therapeutic nihilism , chemotherapy alone failed cure patient . It estimate 15-20 % colorectal cancer patient present synchronous liver metastasis approximately 50 % patient colorectal tumor develop liver metastasis point course disease . In almost one third case , liver show autopsy site cancer spread . This accordance 20 % - 45 % five-year survival obtain surgical resection hepatic metastasis . Previous study show clear benefit adjuvant chemotherapy metastasectomy liver metastasis . However , study perform 5-fluorouracil without old cytostatic drug . Since new effective agent develop ( e.g . : capecitabine , oxaliplatin bevacizumab ) , adjuvant combination treatment agent might effective . These drug prove activity first line palliative treatment recurrent metastasis . This raise question new effective treatment value adjuvant treatment metastasectomy . As mentioned , two-arm EORTC study : neoadjuvant adjuvant FOLFOX v chemotherapy resectable liver metastasis colorectal cancer almost complete ( Nordlinger et al ) . It expect study show 10 % 3 year DFS benefit favour th treatment arm . Definitive data trial release end 2006 , probably lead adjuvant treatment post metastasectomy standard care . In HEPATCIA trial anticipate use adjuvant XELOX control arm . As mention earlier , 3-year disease free survival patient post metastasectomy liver metastasis approximately 25 % . There data available effectivity XELOX regimen adjuvant treatment metastasectomy colorectal cancer metastasis . The EORTC study design demonstrate 10 % improvement 3y DFS . Assuming study positive , 3 year DFS would 35 % control arm ( XELOX post liver resection ) . Since bevacizumab inhibits angiogenesis , require growth metastasis , drug may valuable adjuvant setting . Several study investigate value drug combination fluoropyrimidines adjuvant regimen resection primary colorectal cancer . However , moment mature data available study . Therefore , assume increase 3-year disease free survival 10 % , 45 % XELOX bevacizumab treatment arm . This study therefore evaluate patient resectable liver metastasis without extra-hepatic disease , investigate whether capecitabine , oxaliplatin bevacizumab regimen superior capecitabine oxaliplatin alone apply adjuvant treatment , order extent disease free overall survival .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Signed write informed consent obtain prior studyspecific procedure . Age ≥ 18 year . Liver metastases radically resect ( R0 resection ) . Study medication start ≥4 ≤ 8 week post liver surgery . Histologically confirm liver metastasis colorectal cancer surgery . ECOG performance status 0 1 . Adequate hematology : ANC ≥1.5 x 109/L , platelet ≥100 x 109/L , Hb ≥5.5 mmol/L , INR ≤ 1.5 , APTT &lt; 1.5 X UNL . Adequate biochemistry : total bilirubin ≤1.5 UNL , ASAT ALAT ≤2.5 x UNL , alkaline phosphatase ≤2.5 x UNL , serum creatinine ≤1.5 UNL . Urine dipstick &lt; 2+ protein . Extrahepatic metastatic disease . Prior adjuvant chemotherapy give &lt; 6 month prior detection liver metastasis . Prior non colorectal malignancy . Bleeding diathesis coagulation disorder need fulldose anticoagulation . Major surgical procedure &lt; 4 week prior start study treatment . Females positive pregnancy test ( within 14 day treatment start ) . Lactating woman . Fertile woman ( &lt; 2 year last menstruation ) woman childbearing potential willing use effective mean contraception . History psychiatric disability judge investigator clinically significant , preclude informed consent interfere compliance oral drug intake . Clinically significant ( i.e . active ) cardiovascular disease e.g . cerebrovascular accident ( ≤6 month prior randomization ) , myocardial infarction ( ≤1 year prior randomization ) , uncontrolled hypertension receive chronic medication , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication . Known peripheral neuropathy , include oxaliplatin induce neuropathy &gt; grade Absence deep tendon reflex sole neurological abnormality render patient ineligible . Organ allograft require immunosuppressive therapy . Serious , nonhealing wound , ulcer , bone fracture . Current recent ( within 10 day prior study treatment start ) use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose . Chronic , daily treatment highdose asprin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication ( know inhibit platelet function dos use treat chronic inflammatory disease ) . Patients render eligible change treatment COX II inhibitor . Chronic treatment corticosteroid ( dose ≥ 10 mg/day methylprednisolone equivalent exclude inhaled steroid ) . Serious intercurrent infection ( uncontrolled require treatment ) . Current recent ( within 28 day prior randomization ) treatment another investigational drug participation another investigational study . Patients know allergy Chinese hamster Ovary cell proteins recombinant human humanize antibody excipients bevacizumab formulation , platinum compound component study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Radical resection</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Hepatica</keyword>
</DOC>